Houston, Texas, January 25, 2023 (GLOBE NEWSWIRE) — Herborium® Group, Inc. (OTC pink: HBRM), www.Herborium.com, www.acnease.com a Botanical therapies® Company and the provider of patented all botanical medicines (Botanical Therapeutics®) and an interactive advanced content platform focused on dermatological and other health and wellness issues, shares a Updated shareholder letter Part 2 of the CEO, Dr. Agnes Olszewski.
To our valued shareholders
Following last week’s Shareholder Letter Part 1, this Part 2 presents the main focus for 2023 and beyond. This plan emerges from the analysis of leading market and science trends reshaping our space, and is based on previously reported changes and advancements made in 2022.
One of the most important trends in the health and beauty industry is the fusion of clinical skincare with natural skincare to create clinically validated “hybrid” products that really work while maintaining their natural ingredient profile.
Herborium’s acne treatment represents such a unique product. We are currently working on the second generation of this clinically validated skincare solution that has better consumer characteristics (wider application and simpler treatment routine) and an improved business profile (higher margins)
The company also approaches the most advanced science in clinical skin care products based on stem cells. We are working to add two highly innovative products in this category to our product portfolio for 2023
Since Herborium has an established customer base and strong brand recognition, cooperating with the product developers is the most economical and appropriate way to access innovative products. We are currently in advanced discussions with two companies – one from the US and the second from South Korea, which is well known in the cosmetics and skin care industry for high-performance biotechnology applications in skin care.
As reported in Part 1 of the Shareholder Letter, Herborium has already done so started the transformation process From a product company to a content and product player in the natural skin care and wellness industry. As the demand for natural, safe and sustainable products continues, the important and challenging advancement consists of combining natural scientific knowledge and traditional medical knowledge (information) in this field and making it accessible to professionals and end users alike in a user-friendly way. This creates added value for the customer and additional revenue streams (paid advice in skin care, beauty, nutrition, etc.) for the company.
We expect to make aggressive progress towards completing and launching this AI (artificial intelligence) powered platform in 2023
Monitor shareholder value
Leveraging the growing use of technology and the company’s perfect fit in a rapidly growing domestic and global market for natural health products ($166 billion by 2023; expected to reach $347.5 billion globally by 2029), Herborium® expects further enhance shareholder value. In addition, we intend to continue our efforts to minimize debt, control dilution, increase profitability and reduce costs – all to further enhance Corporate valuation and shareholder value.
About Herborium Group, Inc.
Herborium Group, Inc. is a botanical therapeutics® company that develops, licenses and markets proprietary plant-based medicines for consumers and healthcare professionals. The company’s business model focuses on emerging market opportunities, led by the growth of a new market sector that sits between expensive, risky, ethical pharmaceuticals and classic nutraceuticals (supplements). The company uses clinical validation and a proactive regulatory strategy to establish and maintain a distinctive advantage. Herborium has secured a pipeline of botanical-based products. Herborium Group sells its products in the United States, United Kingdom and continental Europe through a network of distributors, specialty stores and e-commerce.
For more information, go to www.herborium.com, www.acnease.com , www.acnease.frand www.acnease.eu
Safe Harbor Statement: This press release contains forward-looking statements regarding the results of operations of Herborium Group, Inc. that involve risks and uncertainties. The actual future results of the Company may differ materially from those discussed. The Company intends that such statements about the Company’s future expectations, including future revenues and earnings, and all other forward-looking statements are subject to the “Safe Harbors” provision of the Private Securities Litigation Reform Act of 1995.